Application for registration of erythromycin lactobionate for injection accepted
January 15, 2026
Source: drugdu
68
Fosun Pharma (600196) announced on January 14 that its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has recently had its drug registration application for injectable erythromycin lactobionate accepted by the National Medical Products Administration.
This drug is a chemical drug intended for use in treating infections caused by specific susceptible strains of microorganisms when oral administration is not feasible or the severity of the infection requires rapid attainment of high erythromycin serum concentrations; for the prevention of initial rheumatic fever; for the prevention of recurrence of rheumatic fever; and for the prevention of bacterial endocarditis.
https://finance.eastmoney.com/a/202601143619173587.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- 1.2 Billion Yuan! Sino Biopharm Acquires Another Pharmaceutical Company January 15, 2026
- Breakthrough! Changshan Pharmaceutical’s enoxaparin sodium injection receives FDA approval in the United States, marking a new chapter in its overseas market journey! January 15, 2026
- Kelun and Grand Pharmaceuticals compete for the first generic version of a blockbuster heart failure drug! January 15, 2026
- Xuesaitong soft capsules are the company’s exclusive core dosage form January 15, 2026
- Hualan Biological’s investee company’s application for marketing authorization of adalimumab injection has been accepted January 15, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
